Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Most investors are happy with the major changes for the good of the patients and realize that a major upgrade in share price is inevitable.
Some of the changes are Lancet Journal Publication, Money from Silicon Valley Bank, OCAT indorsement from NIH, Patents for Blood Platelets, New management that can take OCAT to the top. IMO
Silicon Valley Bank Money is in OCAT's pocket for a reason. The good of the patients that will be helped.
Clearly seen, $OCAT has the Green.
$OCAT cells have potency, this major change of understanding at the NIH is for the good of the patients.
Quote:
"possible $50 million in grants."
"There's that $50M figure again that was mentioned in the SVB language?"
A look at insider trading.
https://en.wikipedia.org/wiki/Insider_trading
OCAT previously: Advanced Cell Technology has made great strides, especially in the last several months. ... it was a turning point at ACT (soon to be known as Ocata Therapeutics ). .... patent 8822218 covering methods of manufacturing dendritic cells using a ... Being able to produce blood and platelets will be an extremely...
Aug 25, 2015
I will ask this question. What will go right with OCAT? Often, amazing unexpected and expected things happen. OCAT has made it through many so called impossible situations winning the obstacle course game hands down over and over again.
It is difficult for some to visualize their goals met without seeing roadblocks. Sometimes they do not plan on success anyway, they have another agenda.
What would i expect you to say is the real question? Sticking with the facts.
OCAT moved up to the NASDAQ when the naysayers said it would never happen.
OCAT written up in the Lancet with Scientific Peer Reviewed success with medical genius success in Macular Degeneration patient improvements a first in medical history. The naysayers said it would never get in the Journal. Success in patient turned out 20/40 from 20/400 for real.
OCAT was given respectability by the banking community with A-ranking Silicon Valley Bank giving to OCAT. Naysayers said never.
Government gave grant to OCAT, everybody or most said never to that one.
What's next? tomorrow? So many possibilities to keep people on their toes. Last time OCAT was this low five years ago it gaped up causing a run up 600% plus with the ralley monkey and all. And all they had was success with rats on the books. Now OCAT has 20 patients information sandbagged that can come out anytime they choose and 4 years of safety and improvment with the treatments and new medical regenerative restoration patents galore.
OCAT "targets" with an s.
From the NIH project information:
"Importantly, ACT has demonstrated that its hESC-MSCs exert therapeutic effects in several autoimmune disease models"
Aim 1 will determine minimal effective and maximum tolerated doses of ACT's hESC-MSCs for reducing LN disease severity in lupus-prone MRL/lpr mice and compare the effects to those of human umbilical cord (hUC)-derived MSCs (which are showing promise in human clinical trials for lupus).
Aim 2 will define the molecular and cellular targets of hESC-MSC therapeutic activity in tissues/sera from mice injected in Aim 1 and compare these effects to those of hUC-MSCs.
"So could defining cell targets mean other autoimmune diseases---------> more grants? It says SEVERAL autoimmune disease models....we know of 6 to date, and this grant is specific to lupus nephritis." Post from Stemdynasty.
The 1 to 5 multi billion dollar OCAT-evaluations came from the words of OCATA Therapeutics Inc. Director of Business Development Matthew Vincent.
https://www.linkedin.com/in/matthewvincent
If your doing good your looking good, no matter what color.
$OCAT partnering deals ahead. OCAT value is between 1 and 5 billion.
Thanks OCATA for this amazing opportunity.
$OCAT ... Volume can be indicater of urgency and increased intensity. Sudden higher volume can provides hints that a significant move may be eminent.
Huge OCAT volume.
Saxxie: "Reported AH:
Upside Mover:
(+) OCAT, Wins Phase 1 Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases to fund more preclinical development of Mesenchymal Cell product to treat different types of lupus."
$OCAT on Nasdaq Biggest Percentage Gainers - Markets Data Center - WSJ.com
Monday, August 24, 2015 - 1:32 pm ET
Price Chg % Chg Volume
1 HMS Holdings (HMSY) $10.73 1.89 21.38 3,180,628
2 VelocityShares VIX Medium Term ETN (VIIZ) $17.43 2.76 18.81 5,564
3 Ocata Therapeutics (OCAT) $4.50 0.69 18.11 1,041,458
Go OCAT for patients in need !!!
$OCAT Buisness validated by top rated Silicon-Valley-Bank.
$OCAT Science validated by Lancet Peer Reviewed Journal.
$OCAT Lupus program validated by Gov.
$OCAT is in: This Week’s Pre-Market Ratings: CBS Corporation (CBS), TrueBlue, Inc. (TBI), Superior Industries International, Inc. (SUP), iStar Inc. (STAR), Ocata Therapeutics, Inc. (OCAT) Ocata Therapeutics, Inc. (OCAT) is a good stock in the Biotechnology industry Wallstreet Scope
Business
by Kara Harper - Aug 24, 2015 3:32 am EDT
The industry knows Silicon Valley Bank is "top notch", Silicon Valley Bank gave Ocata legitimacy from a financial perspective.
Silicon Valley Bank is one of the most legitimate financial institutions in the country.
Ocata now has incentive to execute and deliver.
Silicon Valley Bank has longer term opportunity that is standing before them.
OCAT steps up to the launching-pad countdown.
These are OCAT view points from the web.
The patients that can be transfered from affliction to a better condition are amazing and worthy of OCAT RPE benefits.
Sometimes a mako is caught leaning the wrong-way.
Here is an example.
No escape. A killer whale with a Mako shark in its grasp. After stunning the shark, the orca grasps the dazed creature and flips it upside down. When sharks are quickly flipped upside down, they enter a paralysed state known as 'tonic immobility' - making for an easy meal
http://www.dailymail.co.uk/sciencetech/article-1231454/Killer-whales-Death-karate-chop-deadly-tactic-used-orcas-sharks.html
OCAT quote: "Ocata is the only company with over 4 years of safety on humans injected in pure retinal pigment epithelium NOT stem cells, whatsoever, and they claim we don't even have 12 months of data. Not only that, the results were duplicated outside the company in the Asian population, and Ocata's results were published 2 separate times in one of the top peer reviewed medical journals worldwide."
No wonder institutions are buying, and Silicon Valley Bank approves OCAT.
I will reiterate OCAT confirmed success.
"evidence "confirmed" successful engraftment of the RPE cells"
No wonder:
Case for OCAT
reasons: Silicon Valley Bank OK's OCAT
Lancet Peer Review Journal confirms OCAT Science
Institutions are growing in number and buying more shares
Reminds me of the Computer Chips Run in Silicon Valley.
OCATA/Advanced Cell Technology, Inc. OCAT, a leader in the field of ... in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment ... evidence "confirmed" successful engraftment of the RPE cells
http://www.businesswire.com/news/home/20141014006693/en/ACT-Announces-Positive-Results-Clinical-Trials-Published#.Vdc7pX1n5Fs
Multiple Sclerosis
Quality Ocata blastomere pluripotent stem cells are more potent. They reboot the immune system. Better than duct tape. IMhumbleO
Yes, here is another OCAT SuperScience use. Crohn's-Disease-Treatment. OCAT is batting 1000% in this catagory.
Like duct-tape, how many more uses for OCAT-Science?
Perhaps Lupus
Case for OCAT
reasons: Silicon Valley Bank OK's OCAT
Lancet Peer Review Journal confirms OCAT Science
Institutions are growing in number and buying more shares
Reminds me of the Computer Chips Run in Silicon Valley.
Case for OCAT
reasons: Silicon Valley Bank OK's OCAT
Lancet Peer Review Journal confirms OCAT Science
Institutions are growing in number and buying more shares
Reminds me of the Computer Chips Run in Silicon Valley.
OCAT post from Stemdynasty:
"I believe they are short well into the millions of shares, and they are doomed and know it now when the market is collapsing and they could have literally shorting 99% of the rest of the market and made money and the longer they hold short the more they risk losing. The problem they have now is they loaded up on shares in anticipation of the fake article and they are boxed in. They did not put together that laughable article to make a few bucks. It was planned out for months and backed with millions. Now the longer they play this charade the more they stand to lose. They fooled NO ONE"
OCAT catch's eye of SVB. "Moving back to the top of the list, Silicon Valley Bank of Santa Clara, Calif. (held by SVB Financial Group (Stock Quote: SIVB), ranked the highest for large banks, with an A rating, based on June 30 financials"
Lasers, thanks for the information on OCAT.
"The loan comes with a full disclosure to the Bank as to $OCAT's complete bullish plans over the immediate future that the Bank officials obviously endorse as realistic"
Best Regards also!
ACTC/now/OCAT has massive success written about in the Lancet Scientific Peer Reviewed Journal. Now the total patient list consist of 44 patients with safety for up to 4 years and amazing improvement in eyesight when no other company has obtained such a gift to mankind.
http://time.com/3507094/stem-cells-eyesight/
OCAT debt free, 10 million more to totals.
OCATA twitt: Get ready for this Crazy little thing called love. Be cool relax get ready.
https://twitter.com/OcataThx/status/633722570819432448
Roseanne Barr Revealed she's Going Blind From Macular-Degeneration.
OCATA Therapeutics Inc. OCAT
Imagine OCAT partner/buyout with many programs.
""The treatment stopped the progression of disease in 17 out of 18 patients after six months, and even more promising, it actually helped improve vision in 10 of 18 of those patients."
And today, 44 patients with OCAT success.
When OCAT brought the patient eyesight to 20/40 from 20/400 and stablized all the patients over a four year period it means something. The Lancet Scientific Peer Reviewed Journal agrees. This is truthful.
Please remember this: compelling reasons to get OCAT.
hschlauch
"Reasons Why I Choose to Invest in Ocata"
"The current share price is meaningless. The intermediate and long term value is undeniable. I will continue to invest in this company for years to come. Some of my personal reasons..."
"1. RPE Function - The replacement of RPE cells fits elegantly into the physiology of the macula. It absorbs light and thus helps with vision, supplies nutrients to photoreceptors, digests destroyed photoreceptor outer segment membranes and allows photoreceptors to renew, secretes factors and signaling molecules to communicate with endothelial or immune system cells, and chooses to either silence or activate immune reactions. Visual function requires interactions between both RPE and photoreceptors. You can rescue photoreceptors. You can try to replace only photoreceptors, but they won't survive without the RPE.
2. RPE Transplants Prevent Progression of Dry AMD to Wet AMD - wet AMD follows the destruction of RPE and photoreceptors. Abnormal blood vessels grow when the waste products of dead photoreceptor and RPE accumulate. Called drusen, these waste deposits break down the Bruchs membrane and lead to neovascularization, or the wet form of AMD. See Regeneron.
Replacing or preventing the destruction of RPE and photoreceptor prevents the accumulation of drusen, thus preventing neovascularization.
3. Market Opportunity - The American Society of Retinal Specialists estimate 15 million Americans have AMD. No approved therapies exist for SMD or AMD.
4. Impenetrable Patent Estate - Includes the manufacturing, formulary, and therapeutic use of RPE from any pluripotent source. Similar photoreceptor progenitor patents are pending. They also have 200- some global patents pending in addition to hemangioblast-derived MSC patents.
5. Sustained Efficacy and Safety in Advanced Dry AMD Cases - Over four years of sustained visual acuity improvements or stabilization. No safety issues related to injected cells.
6. Credibility - published data in peer reviewed journals."
"There is absolutely no reason for this stock to be down any day for any reason while undervalued or to be priced at less than $15.00 per share based on the reported potential remedies. Only the market manipulators and pros cause the valuation distortions in the market place" quote: